Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces that Eli Lilly & Company (Lilly) has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
- Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces that Eli Lilly & Company (Lilly) has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
- Lilly is leading further development and potential commercialization of the Phase 1 immunometabolism-targeting therapy.
- Sitryx and Lilly entered into an exclusive global licensing and research collaboration agreement in March 2020 , under which Sitryx received an upfront payment of $50 million and Lilly made a $10 million equity investment in the Company.
- Sitryx is using the proceeds to advance its proprietary pipeline of immunometabolism-targeting therapies into clinical development.